


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Starsportned

STAR SPORTS MEDICINE CO., LTD.

北京天星醫療股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01609)

VOLUNTARY ANNOUNCEMENT

SHARE REPURCHASE PLAN

This announcement is made by Star Sports Medicine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep its shareholders and potential investors informed of the latest developments of the Group.

The board of directors (the “**Board**”) of the Company hereby announces that, at the 2025 annual shareholders’ meeting held by the Company on June 26, 2026, the shareholders have considered and approved the Proposal regarding the Proposed Grant of General Mandate to Repurchase the H Shares, whereby a general mandate is granted to the Board to repurchase the Company’s H shares (the “**Repurchase Mandate**”). Pursuant to the Repurchase Mandate, the Company is authorized to repurchase H shares not exceeding 10% of the total number of H shares in issue as at the date of passing of the relevant resolution (i.e., 5,483,134 H shares). The Board has resolved to implement the H share repurchase plan under the aforementioned Repurchase Mandate in due course. During the period when the Repurchase Mandate is in effect, and subject to compliance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), the Articles of Association and applicable laws and regulations, the Company may repurchase its H shares from time to time on the open market up to a maximum aggregate amount of not exceeding 2.90 million H shares, representing approximately 5.29% of the total number of H shares in issue of the Company as at the date of this announcement. Pursuant to Rule 10.06 of the Listing Rules, the price paid by the Company for the share repurchase shall not exceed 105% of the average closing price of the shares as quoted on the Stock Exchange for the five trading days immediately preceding the relevant repurchase transaction.

The shares repurchased will be held as treasury shares. The Company intends to fund the share repurchase with its internal resources. Such treasury shares are intended to be used for resale, equity incentive plans or other purposes permitted by applicable laws and regulations. If the treasury shares are resold or used for equity incentive plans, the Company will strictly comply with the provisions of the Listing Rules, relevant disclosure requirements and the principle of fairness to shareholders.

The Company will not conduct any share repurchase to such an extent as would, in the circumstances, result in the Company failing to comply with the applicable public float requirements under the Listing Rules. The Company will not repurchase H shares from core connected person(s). The Company will fulfill its relevant reporting and disclosure obligations including the publication of next day disclosure returns and monthly returns in a timely manner with respect to any share repurchase, changes in treasury shares and/or the resale or transfer of treasury shares in accordance with the Listing Rules and other applicable laws and regulations.

The Board has also authorized the Chairman of the Board of the Company to handle all matters relating to the aforementioned H share repurchase at his sole discretion, including but not limited to approving and issuing relevant announcements, and issuing transfer, withdrawal and other relevant instructions to the Company's share registrar. The Board is of the view that conducting a share repurchase at an appropriate time reflects the Company's confidence in its business prospects and long-term value, and facilitates enhancing the value per share of the Company and the overall shareholders' return, which is in the interests of the Company and shareholders as a whole.

The Company will fulfill its information disclosure obligations regarding the progress of the share repurchase plan in due course in accordance with the provisions of the Listing Rules and other applicable laws and regulations.

Shareholders and potential investors are reminded that the share repurchase will be subject to market conditions and at the sole discretion of the Board. There is no assurance as to the timing, quantity or price of any share repurchases. Therefore, shareholders and potential investors are advised to exercise caution when dealing in the shares.

By order of the Board
Star Sports Medicine Co., Ltd.
Mr. Dong Wenxing
Chairman of the Board and Executive Director

Hong Kong, August 18, 2026

As at the date of this announcement, the Board comprises Mr. Dong Wenxing and Mr. He Lu as executive Directors; Ms. Zhang Di, Mr. Chang Xi, Mr. David Guowei Wang, Ms. Yi Lin and Mr. Zhou Quan as non-executive Directors; and Mr. Lyu Zhenlin, Mr. Deng Yu, Mr. Liu Baojie and Mr. Wang Chunfei as independent non-executive Directors.